Literature DB >> 28072788

CRISPR therapeutics push into human testing.

Cormac Sheridan.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28072788     DOI： 10.1038/nbt0117-3

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  8 in total

1.  Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.

Authors:  Ranjan Batra; David A Nelles; Elaine Pirie; Steven M Blue; Ryan J Marina; Harrison Wang; Isaac A Chaim; James D Thomas; Nigel Zhang; Vu Nguyen; Stefan Aigner; Sebastian Markmiller; Guangbin Xia; Kevin D Corbett; Maurice S Swanson; Gene W Yeo
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

2.  Sangamo's landmark genome editing trial gets mixed reception.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2018-10-11       Impact factor: 54.908

Review 3.  Druggable Transcriptional Networks in the Human Neurogenic Epigenome.

Authors:  Gerald A Higgins; Aaron M Williams; Alex S Ade; Hasan B Alam; Brian D Athey
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

4.  Genome editing technologies and their potential to treat neurologic disease.

Authors:  Nicolas N Madigan; Nathan P Staff; Anthony J Windebank; Eduardo E Benarroch
Journal:  Neurology       Date:  2017-09-20       Impact factor: 9.910

5.  Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.

Authors:  Samuel Lessard; Laurent Francioli; Jessica Alfoldi; Jean-Claude Tardif; Patrick T Ellinor; Daniel G MacArthur; Guillaume Lettre; Stuart H Orkin; Matthew C Canver
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

6.  Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.

Authors:  Yunfei Liao; Lulu Chen; Yong Feng; Jacson Shen; Yan Gao; Gregory Cote; Edwin Choy; David Harmon; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Oncotarget       Date:  2017-05-02

Review 7.  Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases.

Authors:  Ankit Kumar Dubey; Vijai Kumar Gupta; Małgorzata Kujawska; Gorka Orive; Nam-Young Kim; Chen-Zhong Li; Yogendra Kumar Mishra; Ajeet Kaushik
Journal:  J Nanostructure Chem       Date:  2022-02-14

Review 8.  The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer.

Authors:  Wei Lv; Tao Li; Shanshan Wang; Huihui Wang; Xuemei Li; Shubing Zhang; Lianzi Wang; Yuanhong Xu; Wei Wei
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.